Related Experiment Video
Updated: Aug 12, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 17, 2014
[Heart failure and sudden death]
Tadakazu Hirai1, Hidetsugu Asanoi
1Second Department of Internal Medicine, Toyama Medical and Pharmaceutical University.
Insights
Sudden death in heart failure (HF) patients is complex. While medications and implantable cardioverter defibrillators (ICDs) improve survival, individualized care for left ventricular systolic dysfunction is crucial.
Area of Science:
- Cardiology
- Heart Failure Research
- Sudden Cardiac Death
Context:
- Sudden death in heart failure (HF) patients presents significant clinical challenges.
- Neurohumoral activation is implicated in triggering lethal ventricular arrhythmias.
- Current treatments include pharmacotherapy and device-based interventions.
Purpose:
- To review the complexity of sudden death in heart failure.
- To discuss the role of neurohumoral activation in arrhythmias.
- To evaluate the efficacy and cost-effectiveness of implantable cardioverter defibrillators (ICDs) in patients with left ventricular (LV) systolic dysfunction.
Summary:
- Pharmacological agents like ACE inhibitors, ARBs, and beta-blockers improve survival in HF.
- Prophylactic ICD therapy reduces mortality in LV systolic dysfunction but may not be suitable for all patients.
- Individualized patient care is essential for managing LV systolic dysfunction and preventing sudden death.
Impact:
- Highlights the need for personalized treatment strategies in heart failure management.
- Emphasizes careful consideration of prophylactic ICD therapy's benefits versus costs.
- Contributes to understanding the multifactorial nature of sudden cardiac death in HF patients.
Abstract:
Sudden death in patients with heart failure (HF) is a topic of great complexity. Neurohumoral activation including adrenergic and renin-angiotensin-aldosterone system has been a suspected trigger for lethal ventricular arrhythmias and sudden deaths. Randomized clinical trials have demonstrated that angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists and beta-adrenergic blockers improve survivals in patients with HF. Although prophylactic implantable cardioverter defibrillator (ICD) therapy is effective reducing mortality in patients with left ventricular (LV) systolic dysfunction, the ICD is unlikely to be appropriate for all patients with LV systolic dysfunction. In addition, the effect of routine prophylactic use of ICDs on health care costs must be carefully considered. The care of patients with LV systolic dysfunction should be individualized for each patient.
More Related Videos
Related Concept Videos
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Coronary Artery Disease III: Clinical Manifestations
Introduction Cardiac Emergencies
Heart Failure I: Introduction
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations

